Proactiveinvestors United Kingdom ANGLE PLC https://www.proactiveinvestors.co.uk Proactiveinvestors United Kingdom ANGLE PLC RSS feed en Wed, 16 Jan 2019 01:35:35 +0000 http://blogs.law.harvard.edu/tech/rss Genera CMS action@proactiveinvestors.com (Proactiveinvestors) action@proactiveinvestors.com (Proactiveinvestors) <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140558_13932369/ Fri, 11 Jan 2019 14:05:58 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140558_13932369/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140032_13932360/ Fri, 11 Jan 2019 14:00:32 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111140032_13932360/ <![CDATA[Media files - ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11799/angle-plc-s-parsortix-device-plays-critical-role-in-ground-breaking-new-cancer-research-11799.html Fri, 11 Jan 2019 13:03:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11799/angle-plc-s-parsortix-device-plays-critical-role-in-ground-breaking-new-cancer-research-11799.html <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110538_13932118/ Fri, 11 Jan 2019 11:05:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110538_13932118/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110035_13932108/ Fri, 11 Jan 2019 11:00:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111110035_13932108/ <![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090527_13931827/ Fri, 11 Jan 2019 09:05:27 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090527_13931827/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090028_13931824/ Fri, 11 Jan 2019 09:00:28 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190111090028_13931824/ <![CDATA[News - ANGLE device central to new, ground-breaking cancer research ]]> https://www.proactiveinvestors.co.uk/companies/news/212375/angle-device-central-to-new-ground-breaking-cancer-research-212375.html ANGLE PLC (LON:AGL) has revealed its cancer detection device played an important role in research that may one day help prevent the spread of cancer around the body.

Scientists at the University of Basel, Switzerland, used ANGLE’s Parsortix liquid biopsy to isolate metastatic circulating tumour cell clusters - a group of cancer and other cells tethered together as a single mass.

WATCH: ANGLE plc's Parsortix device plays critical role in ground-breaking new cancer research

Once these clusters were identified, the Basel team, led by Professor Nicola Aceto, was able to treat them with repurposed drugs already on the market.

Eye-catching

Eye-catching was the fact that this approach led to a “near total elimination” of metastasis in animal models.

As most people will know, metastasis is where cancer spreads to other parts of the body via the bloodstream. It is responsible for more than 90% of all cancer-related deaths.  

The detail of the research undertaken by the Cancer Metastasis Laboratory was published Friday (Jan 11) as a peer-reviewed article in the prestigious journal, Cell.

ANGLE is seeking US Food & Drug Administration approval for Parsortix.

Ground-breaking

Chief executive, Andrew Newland, said: "The ground-breaking CTC cluster work undertaken over the last three years by the University of Basel, one of ANGLE's leading customers, highlights completely new clinical uses for the Parsortix system with the potential to play a central role in dramatically improving patient outcomes.

“This is a key potential application for Parsortix liquid biopsy once we receive FDA clearance.

“Our ultimate aim is for the Parsortix system to be routinely used for all cancer patients in the future."

---Repeated from Thursday evening---

]]>
Fri, 11 Jan 2019 07:28:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/212375/angle-device-central-to-new-ground-breaking-cancer-research-212375.html
<![CDATA[RNS press release - Second Price Monitoring Extn ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110164113_13931006/ Thu, 10 Jan 2019 16:41:13 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110164113_13931006/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110163602_13930995/ Thu, 10 Jan 2019 16:36:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110163602_13930995/ <![CDATA[RNS press release - BREAKTHROUGH CANCER RESEARCH USING PARSORTIX ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110160102_13930951/ Thu, 10 Jan 2019 16:01:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190110160102_13930951/ <![CDATA[RNS press release - Notice of Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190109070002_13928170/ Wed, 09 Jan 2019 07:00:02 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20190109070002_13928170/ <![CDATA[News - ANGLE’s Parsortix liquid biopsy proving to be more than just a cancer detection device ]]> https://www.proactiveinvestors.co.uk/companies/news/211923/angles-parsortix-liquid-biopsy-proving-to-be-more-than-just-a-cancer-detection-device-211923.html ANGLE plc (LON:AGL, OTCQX:ANPCY) is the firm behind Parsortix – a simple blood test which can help doctors spot the signs of cancer at an early stage.

Blood tests – or liquid biopsies as they are known in the business – were all the rage at some of the world’s biggest cancer conferences in 2018, including the American Society of Clinical Oncology meeting in Chicago over summer.

READ: Liquid biopsies – the breakthrough cancer tests ANGLE is already developing READ: Scientists make big breakthrough with Parsortix

Parsortix is slightly to different to some of its rivals, though: rather than testing for fragments of dead cancer cells, it detects and captures circulating tumour cells (CTCs).

CTCs provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

This method is seen as more reliable because previous tests have shown that fragments of dead cancer cells are present in around a quarter of people over 65 who do not have cancer.

CTCs, on the other hand, “give a complete picture”, because they can only be found in people with cancer.

ANGLE is currently taking its system through the clinic and reported back in October that it was making “good progress” with the study’s enrolment.

Clinical trial to complete in Q1

It is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

With the progress made so far, it expects the trial to be completed by the end of March.

“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis,” said chief executive and founder Andrew Newland.

“This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”

Foetal abnormalities

The cancer arena is where Parsortix is gaining the most traction currently – more than 200 of its devices are in use around the world.

But ANGLE recently made a breakthrough when the system showed promise in harvesting foetal cells which could help detect abnormalities such as Down’s Syndrome in unborn children.

It is estimated that current non-invasive techniques identify less than 10% if all serious birth defects. Parsortix, by contrast, could pave the way for broader genetic screening.

READ: ANGLE finds a new angle for Parsortix

In the small-scale study, Parsortix was able to distinguish between male and female chromosomes and, in one case, correctly identified trisomy 21, the marker for Down’s.

Parents and doctors are willing to pay a hefty price to ensure the health of their unborn babies, with the non-invasive prenatal testing market estimated to be worth around US$600mln. Analysts expect it to grow to US$1bn a year by 2022.

]]>
Thu, 03 Jan 2019 09:35:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/211923/angles-parsortix-liquid-biopsy-proving-to-be-more-than-just-a-cancer-detection-device-211923.html
<![CDATA[RNS press release - Issue of LTIP Options and Share Options ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181221070003_13912406/ Fri, 21 Dec 2018 07:00:03 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181221070003_13912406/ <![CDATA[News - ANGLE names diagnostic pathology expert Dr Joseph D Khoury as a scientific advisor ]]> https://www.proactiveinvestors.co.uk/companies/news/210093/angle-names-diagnostic-pathology-expert-dr-joseph-d-khoury-as-a-scientific-advisor-210093.html ANGLE plc (LON:AGL) (OTCQX:ANPCY) has announced the appointment of Dr Joseph D Khoury as a scientific advisor to the company's established Scientific Advisory Board.

The AIM-listed liquid biopsy company pointed out that Khoury is a recognised expert in diagnostic pathology and has significant experience in the cytological and morphological analysis of cancer cells.

READ: ANGLE acquires remaining stake in US subsidiary from Parsortix inventor

It added that his expertise is therefore highly relevant to ANGLE's continuing development of its ParsortixTM system as the liquid biopsy platform of choice for harvesting and analysing circulating tumour cells and other rare cells from blood as a means of diagnosing and monitoring disease.

The group said Khoury is a tenured Professor of Pathology and Laboratory Medicine at The University of Texas MD Anderson Cancer Center in Houston, Texas and is the Executive Director of the MD Anderson Cancer Network for the Division of Pathology and Laboratory Medicine and the Director of the MD Anderson Institutional Immunohistochemistry Laboratory.

ANGLE founder and chief executive, Andrew Newland, commented: "Our Parsortix system has been shown to enable the efficient harvesting of circulating cancer cells and other rare cells in patient blood.

“Dr Khoury's expertise in interpreting these cells and their relevance to a patient's condition, and potentially their prognosis and treatment, is expected to open up new possibilities for the use of Parsortix system. “

]]>
Wed, 28 Nov 2018 07:31:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/210093/angle-names-diagnostic-pathology-expert-dr-joseph-d-khoury-as-a-scientific-advisor-210093.html
<![CDATA[RNS press release - LEADING US HEMATOPATHOLOGIST APPOINTED AS ADVISOR ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181128070008_13882757/ Wed, 28 Nov 2018 07:00:08 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181128070008_13882757/ <![CDATA[RNS press release - Holding(s) in Company ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181113171038_13865659/ Tue, 13 Nov 2018 17:10:38 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181113171038_13865659/ <![CDATA[News - ANGLE acquires remaining stake in US subsidiary from Parsortix inventor ]]> https://www.proactiveinvestors.co.uk/companies/news/208492/angle-acquires-remaining-stake-in-us-subsidiary-from-parsortix-inventor-208492.html ANGLE plc (LON:AGL) now owns 100% of its North American subsidiary after buying out Georgi Hvichia’s 9.47% stake.

Hvichia is the original inventor of ANGLE’s Parsortix cancer detection technology. As such, he still holds a stake in ANGLE North America (ANAI) but the company has issued £467,500 worth of shares to acquire it.

READ: ANGLE finds new angle for cancer detection device

It means that Hvichia, who is currently a director of ANAI but will move to a scientific advisory board member role, now owns 1.08mln ANGLE shares, around 0.76% of the total share capital.

The AIM-quoted firm said the agreement gives it a clean 100% ownership of all its group companies, adding that the US subsidiary is particularly important as it owns core intellectual property related to Parsortix.

“We are pleased to reach an agreement with Georgi Hvichia, the original inventor of the Parsortix microfluidic technology, to acquire his remaining shareholding in our US operating subsidiary in exchange for ANGLE plc shares,” said chief executive Andrew Newland.

Angle shares were untraded at 96.2p in early deals on Monday.

]]>
Mon, 05 Nov 2018 08:34:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/208492/angle-acquires-remaining-stake-in-us-subsidiary-from-parsortix-inventor-208492.html
<![CDATA[RNS press release - Acquisition of outstanding shares ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181105070006_13854132/ Mon, 05 Nov 2018 07:00:06 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181105070006_13854132/ <![CDATA[RNS press release - Price Monitoring Extension ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181102140035_13853552/ Fri, 02 Nov 2018 14:00:35 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181102140035_13853552/ <![CDATA[RNS press release - Appointment of Dr Jan Groen as NED ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181101070005_13850480/ Thu, 01 Nov 2018 07:00:05 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181101070005_13850480/ <![CDATA[RNS press release - Result of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181030162150_13848238/ Tue, 30 Oct 2018 16:21:50 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181030162150_13848238/ <![CDATA[Media files - ANGLE PLC sees big opportunities in non-invasive prenatal testing ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/11017/angle-plc-sees-big-opportunities-in-non-invasive-prenatal-testing-11017.html Mon, 29 Oct 2018 10:52:00 +0000 https://www.proactiveinvestors.co.uk/companies/stocktube/11017/angle-plc-sees-big-opportunities-in-non-invasive-prenatal-testing-11017.html <![CDATA[News - ANGLE finds a new angle for cancer detection device as it screens pregnant women ]]> https://www.proactiveinvestors.co.uk/companies/news/207996/angle-finds-a-new-angle-for-cancer-detection-device-as-it-screens-pregnant-women-207996.html ANGLE plc(LON:AGL, OTCQX:ANPCY) said its device for detecting the early signs of cancer had shown promise harvesting fetal cells.

Parsortix appeared to score well against existing methods of non-invasive prenatal testing (NIPT).

Specifically, it was able to harvest intact cells, which could then be assessed for abnormalities such Down’s Syndrome.

Currently-available technology allows for only fragments of dead fetal cells to be collected, which limits the scope for testing an assessment.

Current technology has drawbacks

Parsortix, by contrast, could pave the way for broader genetic screening.

It is estimated that current cell-free fetal DNA non-invasive techniques identify less than 10% of all serious birth defects. 

“A test utilising intact fetal cells could have much wider application than the current cell-free tests,” ANGLE said.

A further limitation of the current method of non-invasive testing is that it relies on next-generation sequencing analysis of cell-free DNA.

This area is currently the domain of a small handful large life sciences companies which closely guard the intellectual property.

The Parsortix method has its own cell-free DNA analysis that doesn’t infringe the competition’s patents.

Presentation of data 

Data from the pilot study of 19 pregnant women will be presented at the Sixth Annual Advances in Prenatal Diagnostics conference in Cambridge, Massachusetts.

Delegates will hear that large fetal cells were identified in every case. 

The test was able to distinguish between male and female chromosomes and, in one case, correctly identified trisomy 21, the marker for Down’s.

“This was a small-scale pilot study and, whilst highly encouraging, substantial further work will be necessary to develop an effective NIPT [non-invasive] test,” ANGLE said. 

The size of the non-invasive prenatal testing market is estimated to be around US$600mln and is expected to grow to US$1bn a year by 2022.

Commercial opportunity

Recognising this, but unwilling to impede the current traction it is gaining for Parsortix in the cancer arena, ANGLE is looking for an outside partner to help commercialise the fetal cell test opportunity.

"Non-invasive prenatal testing is a major new market for the Parsortix system and a potential solution to the current limitations of NIPT, providing a more comprehensive diagnosis of fetal abnormalities for mothers at risk of an affected pregnancy,” said ANGLE founder and chief executive, Andrew Newland. 

“ANGLE's product-based approach to liquid biopsy enables us to leverage partnerships with third parties, which we are developing in the NIPT space, an established and fast growing large-scale market."

The shares rose 4%, valuing ANGLE at £58mln.

]]>
Mon, 29 Oct 2018 07:43:00 +0000 https://www.proactiveinvestors.co.uk/companies/news/207996/angle-finds-a-new-angle-for-cancer-detection-device-as-it-screens-pregnant-women-207996.html
<![CDATA[RNS press release - PARSORTIX SHOWS CAPABILITY TO HARVEST FETAL CELLS ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181029070007_13845082/ Mon, 29 Oct 2018 07:00:07 +0000 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181029070007_13845082/ <![CDATA[News - Over 75% of patients now enrolled into ANGLE’s Parsortix clinical study ]]> https://www.proactiveinvestors.co.uk/companies/news/207826/over-75-of-patients-now-enrolled-into-angles-parsortix-clinical-study-207826.html ANGLE PLC (LON:AGL) continues to make “good progress” with the enrolment for the clinical study of its Parsortix cancer detection technology.

So far, over 75% of the required 400 patients – 200 with cancer and 200 healthy – have been enrolled in the study.

READ: Scientists make major breakthrough with Parsortix

ANGLE is looking to become the first company to receive Food and Drug Administration clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.

Given the progress to-date, the AIM company now expects the study to be completed during the first quarter of 2019.

Away from the trial, ANGLE has been carrying out more work of its own on Parsortix, which has yielded “new insights” into the system.

Multi-billion-dollar market

“Our significant and sustained efforts to complete the clinical and analytical studies needed to support our FDA submission are progressing well,” said chief executive Andrew Newland.

“We believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis.”

He added: “This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy, securing a leading position in the emerging multi-billion-dollar liquid biopsy market.”

Shares fell 4.4% to 41.1p.

]]>
Thu, 25 Oct 2018 08:27:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/207826/over-75-of-patients-now-enrolled-into-angles-parsortix-clinical-study-207826.html
<![CDATA[RNS press release - Good Progress with FDA Studies ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181025070005_13841591/ Thu, 25 Oct 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181025070005_13841591/ <![CDATA[RNS press release - Notice of AGM ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181009070010_13820925/ Tue, 09 Oct 2018 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20181009070010_13820925/ <![CDATA[News - Scientists make major breakthrough with ANGLE’s Parsortix liquid biopsy system ]]> https://www.proactiveinvestors.co.uk/companies/news/203676/scientists-make-major-breakthrough-with-angles-parsortix-liquid-biopsy-system-203676.html Researchers have shown that ANGLE PLC’s (LON:AGL) Parsortix liquid biopsy system can be used to identify people with glioblastoma – an aggressive type of brain cancer.

Parsortix detects and captures circulating tumour cells (CTCs), which provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

READ: ANGLE on track to conclude FDA study by year-end

It had previously been thought that clusters of CTCs in brain cancers would not pass through the blood-brain barrier meaning ANGLE’s system wouldn’t have been able to detect them.

But a team of scientists from the University of Basel in Switzerland has disproved that theory, showing that as well as singular CTCs, clusters of CTCs will pass through the blood-brain barrier and can be harvested for analysis using the Parsortix system.

“The glioblastoma work is a further example of ground breaking research being undertaken by a Parsortix customer in addition to ANGLE's own efforts to commercialise the Parsortix system,” said chief executive Andrew Newland.

“University of Basel and their collaborators are working on the application of this approach for the treatment of glioblastoma patients and we look forward to reporting further developments in due course.”

Shares rose 5.2% in early deals on Tuesday to 48.9p.

]]>
Tue, 28 Aug 2018 08:18:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/203676/scientists-make-major-breakthrough-with-angles-parsortix-liquid-biopsy-system-203676.html
<![CDATA[RNS press release - Parsortix shows evidence of CTCs in glioblastoma ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180828070010_13768798/ Tue, 28 Aug 2018 07:00:10 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180828070010_13768798/ <![CDATA[News - ANGLE on track to conclude FDA study by year-end ]]> https://www.proactiveinvestors.co.uk/companies/news/201511/angle-on-track-to-conclude-fda-study-by-year-end-201511.html Med-tech specialist ANGLE PLC (LON:AGL) has confirmed it is on target to complete by the end of the year a US Food & Drug Administration study of cancer detection device, Parsortix.

A total of 400 people at four leading oncology centres are taking part in the trial, which its hoped will help the company gain Class II clearance for the device, which harvests intact circulating tumour cells.

“Clearance by the FDA is considered the global standard for approval of medical diagnostic systems and ANGLE believes that such clearance would provide ANGLE's Parsortix system with a further competitive differentiation, which would accelerate all forms of commercial adoption of the system in both research and clinical settings,” the company said.

The update was provided alongside full-year results, which showed the company was on a sound financial footing as well as making significant progress operationally.

Ovarian cancer study success

In the year ended April, the R&D team successfully concluded the 400-patient US and European ovarian cancer study, which delivered 95% accuracy identifying benign and malignant pelvic masses. This was significantly better than the current standard of care.

ANGLE has also added some complementary technology to its portfolio following the acquisition of Axela Inc for £3.6mln.

Axela’s main asset is the Ziplex platform, which allows gene expression analysis of cancer cells.

International tie-ups 

Internationally, the company is being recognised for its expertise and has an installed base of Parsortix devices that has grown to 200 from 145 last year.

Alongside academic tie-ups, it now has collaborations with pharma and biotech big hitters QIAGEN, Philips and Abbott.

As is to be expected of a company that’s attempting to prove the clinical and commercial worth of a potential breakthrough device, ANGLE was loss-making. In the 12 months to April 30, the deficit was £7.5mln.

It generated modest revenues and grant income of £700,000. More importantly, it had £7.6mln in the bank at the period-end and has gone out and raised a net £12mln. In other words, it is well-funded.

Continued investment 

"With two successful ovarian cancer studies, the initiation of our FDA clinical studies and three global healthcare companies secured as partners, ANGLE has established worldwide recognition and potential,” said chairman Garth Selvey.

“The acquisition of downstream analysis technology complements the Parsortix system and will, in time, allow us to offer our customers a full 'sample to answer' solution.

“We continue to invest heavily to pursue FDA clearance for the Parsortix system as the first ever FDA cleared clinical device to harvest intact circulating tumour cells for analysis from patient blood.

“Commencement of clinical trials at four prestigious US cancer centres marks a major step forward for the business."

]]>
Wed, 25 Jul 2018 07:37:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/201511/angle-on-track-to-conclude-fda-study-by-year-end-201511.html
<![CDATA[RNS press release - Preliminary Results for year ended 30 April 2018 ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180725070005_13730006/ Wed, 25 Jul 2018 07:00:05 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180725070005_13730006/ <![CDATA[RNS press release - EIS/VCT Advance Assurance and Total Voting Rights ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180724174232_13729839/ Tue, 24 Jul 2018 17:42:32 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180724174232_13729839/ <![CDATA[RNS press release - Result of General Meeting ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180718103423_13722446/ Wed, 18 Jul 2018 10:34:23 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180718103423_13722446/ <![CDATA[RNS press release - Notice of Preliminary Results ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180702070006_13700599/ Mon, 02 Jul 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180702070006_13700599/ <![CDATA[News - finnCap retains 110p target price on ANGLE in the wake of 50p per share placing which raised £12.7mln ]]> https://www.proactiveinvestors.co.uk/companies/news/199608/finncap-retains-110p-target-price-on-angle-in-the-wake-of-50p-per-share-placing-which-raised-127mln-199608.html finnCap has reiterated its 110p target price on ANGLE PLC (LON:AGL) in the wake of the £12.7mln fundraising which the Parsortix liquid biopsy company completed yesterday.

The AIM-listed firm placed 8,400,000 EIS/VCT placing shares, 15,443,282 general placing shares and 1,556,718 subscription shares with new and existing investors all at a price of 50p each raising more than the £12mln initial target following an accelerated bookbuild.

READ: ANGLE announces new share placing in £12mln fundraise

The issue price represents a discount of approximately 8.76% to ANGLE’s closing mid-market price of 54.8p on Friday, 22 June 2018.

In late afternoon trade on Tuesday, ANGLE shares were changing hands at 54.5p, up 0.9% on Monday’s close.

In a note to clients, finnCap analyst Mark Brewer noted that ANGLE has raised the cash “to advance the development of Parsortix clinical applications in breast cancer and ovarian cancer triage pre-surgery as well as prepare for growth ahead of FDA clearance for Parsortix, which we expect in CY 2019.”

The analyst for the ‘house broker’ pointed out that in a trading update for the period to April 2018, ANGLE indicated revenues of £0.7mln, together with better than expected year-end cash of £7.6mln and a £1.1mln tax credit received post period-end.

He added; “Given the later than expected start to the breast cancer study following final IRB approvals and the ongoing optimisation of the ovarian cancer gene panel, forecasts are essentially pushed out by one year.”

Brewer said: “Despite this and the dilution afforded by the placing, our target price rises to 110p, reflecting the clearer path to commercialisation as evidenced by agreements with Abbott and QIAGEN, and knowledge that the FDA trial is well into enrolment.

“We apply a 17.5% discount rate to cashflows and roll forward DCF to FY 2019. The target price implies an enterprise value of c.£157m.”

]]>
Tue, 26 Jun 2018 15:39:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199608/finncap-retains-110p-target-price-on-angle-in-the-wake-of-50p-per-share-placing-which-raised-127mln-199608.html
<![CDATA[RNS press release - Results of Fundraising ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180625182033_13692902/ Mon, 25 Jun 2018 18:20:33 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180625182033_13692902/ <![CDATA[RNS press release - Close of Accelerated Bookbuild ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180625145849_13692639/ Mon, 25 Jun 2018 14:58:49 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180625145849_13692639/ <![CDATA[News - ANGLE announces new share placing in £12mln fundraise ]]> https://www.proactiveinvestors.co.uk/companies/news/199476/angle-announces-new-share-placing-in-12mln-fundraise-199476.html ANGLE PLC (LON:AGL) has announced a conditional placing of new ordinary shares to raise proceeds of £12mln to fund a strengthening of position in the liquid biopsy market.

The AIM-listed medial diagnostics company said it would issue a total of 23,970,000 new ordinary shares at a placing price of 50p each, an 8.7% discount on the last close price of 54.8p.

READ: Liquid biopsies: The breakthrough cancer tests which AIM-listed ANGLE is already developing

The firm added that the placing was being conducted by an accelerated bookbuild process which would open with immediate effect.

ANGLE said the proceeds from the fundraising would be used with its existing cash balance to progress FDA studies, clearance and metastatic breast cancer applications, progress work on the ovarian cancer pelvic mass triage application, progress development of prostate cancer applications, undertake certain incremental product development improvements, and cover ongoing operating expenses.

Andrew Newland, ANGLE chief executive and founder, said: "The new funding will allow us to strengthen our leadership position in the emerging multi-billion dollar liquid biopsy market. The additional funding will strengthen the business in discussions with corporate partners, extend the cash runway significantly past the expected timescale for FDA clearance and will enable us to prepare for revenue growth.”

]]>
Mon, 25 Jun 2018 09:21:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/199476/angle-announces-new-share-placing-in-12mln-fundraise-199476.html
<![CDATA[RNS press release - Proposed Placing of New Ordinary Shares ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180625075002_13691728/ Mon, 25 Jun 2018 07:50:02 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180625075002_13691728/ <![CDATA[News - Liquid biopsies: The breakthrough cancer tests which AIM-listed ANGLE is already developing ]]> https://www.proactiveinvestors.co.uk/companies/news/198198/liquid-biopsies-the-breakthrough-cancer-tests-which-aim-listed-angle-is-already-developing-198198.html Liquid biopsies have been all the rage at this year’s American Society of Clinical Oncology meeting in Chicago.

A liquid biopsy might sound more complicated than it actually is: it is essentially a simple blood test which can be used to help doctors detect cancers at an early stage.

‘Holy grail’

One of the big stories from ASCO 2018 was a test which has been able to detect ten types of cancer.

It works by detecting tiny bits of dead cancer cells in a blood sample and has been labelled as "potentially the holy grail of cancer research".

The test had particularly good results in detecting ovarian and pancreatic cancers, although the number of patients with tumours was small.

“This is potentially the holy grail of cancer research, to find cancers that are currently hard to cure at an earlier stage when they are easier to cure,” said Dr Eric Klein, lead author of the research from Cleveland Clinic’s Taussig Cancer Institute. “We hope this test could save many lives.”

Short of a cure for cancer altogether, scientists think this could be the best way to improve survival rates: seeking out tumours earlier when they are easier to treat.

ANGLE trying something similar

AIM-listed ANGLE plc (LON:AGL) is one of those which has long adopted this philosophy.

It is currently taking its Parsortix liquid biopsy system through the clinic and recently reported that it is making “encouraging progress” with the trials.

Parsortix is slightly different to the much-hyped test unveiled at ACSO: rather than testing for fragments of dead cancer cells, it detects and captures circulating tumour cells (CTCs).

CTCs provide the tell-tale signs of cancer and their capture can allow doctors to more accurately assess treatment options.

Although ANGLE boss Andrew Newland has welcomed the interest generated by the new liquid biopsy, he, perhaps unsurprisingly, thinks Parsortix is a few steps ahead, and not just in terms of timescale.

He points out that the purpose of a test is not just to spot those with cancer, but also to correctly identify those who don’t have the disease.

Parsortix ‘a more complete test’

“This is much more challenging than discriminating known healthy from known cancer. The Cleveland Clinic study has done no work in this area and this is recognised in the comment that the test is five to ten years away from being available.”

Newland reckons false negatives – when someone without cancer is told that they do – could be an issue with the Cleveland Clinic test because of how it works.

Previous studies have shown that fragments of dead cancer cells (what the Cleveland test looks for) are present in around a quarter of people over 65 who do not have cancer.

CTCs, on the other hand, “give a complete picture”, Newland says, because they can only be found in people with cancer.

ANGLE shares were down 1.5% to 54.2p on Monday afternoon.

]]>
Mon, 04 Jun 2018 14:15:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198198/liquid-biopsies-the-breakthrough-cancer-tests-which-aim-listed-angle-is-already-developing-198198.html
<![CDATA[News - ANGLE clinical study making encouraging progress ]]> https://www.proactiveinvestors.co.uk/companies/news/198154/angle-clinical-study-making-encouraging-progress-198154.html ANGLE PLC (LON:AGL, OTCQX:ANPCY) said it is making “encouraging progress” enrolling patients to its clinical trial of the company’s liquid biopsy system Parsortix.

The ANG-002 Food & Drug Administration (FDA) study will focus on metastatic breast cancer.

READ: ANGLE appoints leading prostate cancer surgeon Greg Shaw as scientific advisor

At present 80 of the 400 women taking part have been recruited. They will be split into two groups: one with the disease, the others will be healthy volunteers.

ANGLE has its sights set on becoming the first ever company to receive FDA clearance for a platform that captures and harvests intact circulating tumour cells (CTCs) from patient blood for subsequent analysis. It also hopes to be one of only three FDA cleared liquid biopsy solutions.

Cancer signs

CTCs provide the tell-tale signs of cancer. Their capture can allow doctors to more accurately assess treatment options.

ANGLE said the progress to date suggests the clinical assessment and the parallel analytical studies will complete, as planned, in the second-half.

The primary role of the trial is show that CTCs are harvested from breast cancer patients and not from healthy women.

Exploratory “endpoints” include analysis of harvested cells with quantitative RT-PCR, analysis with fluorescence in situ hybridisation (FISH) and analysis with whole transcriptome sequencing (RNA-Seq), being three of the primary types of downstream analysis beyond cytological analysis.

Tremendous opportunity 

“We continue to believe there is a tremendous opportunity for ANGLE to secure the first ever FDA clearance for a platform that captures and harvests intact circulating tumour cells from patient blood for subsequent analysis,” said chief executive Andrew Newland. 

“This would be a key step in establishing the Parsortix system as the system of choice for CTC liquid biopsy securing a leading position in the emerging multi-billion dollar liquid biopsy market."

]]>
Mon, 04 Jun 2018 07:16:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/198154/angle-clinical-study-making-encouraging-progress-198154.html
<![CDATA[RNS press release - ENCOURAGING PROGRESS IN ANG-002 FDA CLINICAL STUDY ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180604070009_13664808/ Mon, 04 Jun 2018 07:00:09 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180604070009_13664808/ <![CDATA[News - ANGLE appoints leading prostate cancer surgeon Greg Shaw as scientific advisor ]]> https://www.proactiveinvestors.co.uk/companies/news/196880/ANGLE-appoints-leading-prostate-cancer-surgeon-Greg-Shaw-as-scientific-advisor-196880.html ANGLE PLC (LON:AGL) has announced the appointment of leading NHS prostate cancer surgeon Greg Shaw as a scientific advisor to the company.

The AIM-listed firm said, joining its already established Scientific Advisory Board, Shaw brings significant additional prostate cancer and UK NHS clinical experience.

READ: ANGLE upbeat on QIAGEN collaboration ahead of poster presentation

The company said Shaw is a consultant urological surgeon at University College Hospital in London and is a clinical academic with a strong interest in prostate cancer diagnostics and treatment.

ANGLE said Shaw leads several research programmes focused on current weaknesses in the way prostate cancer is treated and is an expert in robotic surgery with a high case volume. He is known for his innovative approach and commitment to quality assurance.

Andrew Newland, founder and chief executive of ANGLE, said: “As we prepare to extend our prostate cancer work, we are delighted that we will be able to benefit from Greg Shaw’s extensive experience in this area.”

He added: “Greg’s understanding of current clinical practice in the UK and the key areas of medical need that liquid biopsy can address will help us to position Parsortix clinical applications for prostate cancer in the future.”  

 

]]>
Mon, 14 May 2018 07:34:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196880/ANGLE-appoints-leading-prostate-cancer-surgeon-Greg-Shaw-as-scientific-advisor-196880.html
<![CDATA[RNS press release - Leading cancer surgeon appointed ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180514070011_13639052/ Mon, 14 May 2018 07:00:11 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180514070011_13639052/ <![CDATA[News - ANGLE upbeat on QIAGEN collaboration ahead of poster presentation ]]> https://www.proactiveinvestors.co.uk/companies/news/196317/angle-upbeat-on-qiagen-collaboration-ahead-of-poster-presentation-196317.html ANGLE plc (LON:AGL, OTCQX:ANPCY) said its co-marketing agreement with the US samples and assay technologies specialist QIAGEN (NYSE:QGEN) is “progressing well”.

The pair are working on combining ANGLE's Parsortix liquid biopsy system to harvest circulating tumour cells in prostate cancer with QIAGEN's downstream AdnaTest gene expression analysis kit.

READ: ANGLE higher as researchers may have found new “high value application” for breakthrough cancer cell capture system

Details of that collaboration are being presented on Thursday (May 3) via a scientific poster at the International Symposium on Minimal Residual Cancer in Montpellier, France.

By combining the technologies the pair hope to create a platform that’s able to predict how prostate cancer patients will react to certain drugs.

ANGLE chief executive Andrew Newland said: "Partnering is a core part of ANGLE's strategy to secure widespread adoption of the Parsortix system right across the market, leveraging the customer base and distribution channels of established players and today's news demonstrates the good progress we have made in our collaboration with QIAGEN towards offering combined solutions for the treatment of cancer."

]]>
Thu, 03 May 2018 07:57:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/196317/angle-upbeat-on-qiagen-collaboration-ahead-of-poster-presentation-196317.html
<![CDATA[RNS press release - Angle & QIAGEN Poster ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180503070004_13628125/ Thu, 03 May 2018 07:00:04 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180503070004_13628125/ <![CDATA[Media files - ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs' ]]> https://www.proactiveinvestors.co.uk/companies/stocktube/9107/angle-plc-s-andrew-newland-on-breakthrough-in-culturing-ctcs--9107.html Thu, 19 Apr 2018 12:51:00 +0100 https://www.proactiveinvestors.co.uk/companies/stocktube/9107/angle-plc-s-andrew-newland-on-breakthrough-in-culturing-ctcs--9107.html <![CDATA[News - ANGLE higher as researchers may have found new “high value application” for breakthrough cancer cell capture system ]]> https://www.proactiveinvestors.co.uk/companies/news/195336/angle-higher-as-researchers-may-have-found-new-high-value-application-for-breakthrough-cancer-cell-capture-system-195336.html Researchers using ANGLE’s Parsortix (LON:AGL) device for capturing circulating tumour cells may have found another “clear high value application” for the system, helping its shares jump higher on Thursday.

For not only have they discovered a method of successfully culturing the cancer cells from blood samples taken using Partsortix, they have also designed a work flow for the process.

WATCH: ANGLE PLC's Andrew Newland on 'breakthrough in culturing CTCs'

This latter point means the results achieved by the team led by Dr Massimo Cristofanilli can be reproduced time and again.

Being able to culture cancer cells outside the body, in this case metastatic cancer cells, allows specialists to “interrogate” them.

This doesn’t involve a spotlight and rubber hose, rather it allows predictive testing of certain drugs to assess whether they will be efficacious.

And as Cristofanilli pointed out: “Widely adopted, this approach has the potential to transform the way we treat cancer patients."

Cristofanilli and his team from the Robert H Lurie Comprehensive Cancer Center and the Feinberg School of Medicine, at Northwestern University, Chicago, presented their findings to the American Association for Cancer Research conference in Chicago. This is one of two leading US oncology conferences and attracts the industry’s key opinion leaders.

The process of harvesting and enriching the samples was only possible because of the microfluidic process used by Parsortix, ANGLE said. Unlike other systems for identifying and extracting cancer cells, the ANGLE device does not use antibodies.

A world first 

Additionally, this is the first time that an optimised workflow has been presented to culture circulating tumour cells (CTCs) ex-vivo (outside the body).

ANGLE chief executive Andrew Newland said: “Firstly, every metastatic breast sample analysed yielded a large number of CTCs, which is a positive sign for our FDA study. 

“Secondly, Northwestern has achieved something that many other Centres before them have failed to do, which is to produce an optimised workflow for reproducibly growing the CTCs. 

“This approach is potentially applicable for every metastatic breast cancer patient and provides another clear high value application for ANGLE's Parsortix system."

The show and tell by the team at Northwestern was one of “multiple presentations” at the American Association for Cancer Research conference showcasing Parsortix and its use in cancer treatment and research.

Approach working 

Newland said the approach of imbedding Parsortix in research activities demonstrated the company’s “strategy of promoting the adoption of its CTC harvesting system as the de facto standard for harvesting cancer cells for analysis is working well and generating further utility and evidence of effectiveness”. 

“The system is compatible with numerous downstream analysis systems and our aim is for it to become the CTC system of choice for cancer liquid biopsy, a growing market that is expected to reach $14bn in the United States alone by 2025. 

“In pursuit of this objective, following highly successful trials in ovarian cancer, ANGLE has a pivotal clinical study for metastatic breast cancer in progress with the aim of becoming the first company ever to receive FDA clearance for a product to harvest CTCs from blood for subsequent analysis."

Around 1pm, ANGLE shares were up 5.5% at 48.5p.

In a note to clients, analysts at 'house' broker finnCap repeated a 108p a share target price on ANGLE pointing out that today's news "adds an entirely new application for ANGLE’s Parsortix system."  

 -- Adds video link, broker comment; updates share price --

]]>
Thu, 19 Apr 2018 07:54:00 +0100 https://www.proactiveinvestors.co.uk/companies/news/195336/angle-higher-as-researchers-may-have-found-new-high-value-application-for-breakthrough-cancer-cell-capture-system-195336.html
<![CDATA[RNS press release - Parsortix in multiple presentations at AACR ]]> https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180419070006_13610231/ Thu, 19 Apr 2018 07:00:06 +0100 https://www.proactiveinvestors.co.uk/companies/rns/1808/LSE20180419070006_13610231/